AKCA - Akcea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.620
+0.670 (+2.40%)
As of 12:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close27.950
Open28.160
Bid28.580 x 800
Ask28.630 x 800
Day's Range27.900 - 28.830
52 Week Range9.900 - 33.985
Volume75,410
Avg. Volume300,192
Market Cap2.45B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.766
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: Galmed Pharmaceuticals and Akcea Therapeutics

    The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors. “If the trade skirmish escalates into a full-blown trade war, that will be a bigger force in the markets than the strong fundamentals,” Carter added.

  • GlobeNewswire7 days ago

    Akcea and Ionis Announce Approval of TEGSEDI(TM) (inotersen) in the European Union

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that TEGSEDITM (inotersen) has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). This follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA). Click here to view the EC`s decision.

  • GlobeNewswire7 days ago

    Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that TEGSEDITM (inotersen) has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). This follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA).

  • PR Newswire13 days ago

    New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

    Results from the study demonstrated that patients treated with TEGSEDI experienced early, sustained and highly significant benefit in both co-primary endpoints:  the modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN), compared to placebo-treated patients. The clinical benefits demonstrated by TEGSEDI were associated with substantial reductions in the transthyretin (TTR) protein, the underlying cause of hATTR amyloidosis.  For the full text of this publication, please visit: https://www.nejm.org/doi/full/10.1056/NEJMoa1716793.

  • ACCESSWIRE15 days ago

    Today's Research Reports on Trending Tickers: Spark Therapeutics and Akcea Therapeutics

    NEW YORK, NY / ACCESSWIRE / July 3, 2018 / U.S. equities closed up on Monday, supported by a rally from the technology sector. However, growing trade concerns continue to weigh on the markets. The Dow ...

  • GlobeNewswirelast month

    Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion of a new study to assess the burden of people living with Familial Chylomicronemia Syndrome (FCS) and its impact on their daily lives. Results from the study known as Re-FOCUS were published on June 11, 2018 in the peer-reviewed journal Expert Review of Cardiovascular Therapy. The web-based global study was conducted among people with FCS treated with volanesorsen, Akcea`s investigational therapy currently under regulatory review in the US, EU and Canada.

  • GlobeNewswirelast month

    Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion of a new study to assess the burden of people living with Familial Chylomicronemia Syndrome (FCS) and its impact on their daily lives. Results from the study known as Re-FOCUS were published on June 11, 2018 in the peer-reviewed journal Expert Review of Cardiovascular Therapy. The web-based global study was conducted among people with FCS treated with volanesorsen, Akcea’s investigational therapy currently under regulatory review in the US, EU and Canada.

  • GlobeNewswirelast month

    Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”), a Konica Minolta company, today announced the launch of hATTR Compass™, a no-cost, confidential genetic testing and genetic counseling program for people with suspected hereditary ATTR (hATTR) amyloidosis. Akcea and Ambry created the hATTR Compass program to empower people with accurate genetic information so they can make informed decisions about their healthcare.

  • ACCESSWIRElast month

    Today’s Free Research Reports Coverage on Agenus and Three More Biotech Stocks

    In today's pre-market research, WallStEquities.com evaluates Affimed N.V. (NASDAQ: AFMD), Agenus Inc. (NASDAQ: AGEN), Akcea Therapeutics Inc. (AKCA), and Akebia Therapeutics Inc. (NASDAQ: AKBA). The Company's shares are trading 8.38% above their 200-day moving average.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...

  • GlobeNewswirelast month

    Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Richard (Rich) A. Moscicki, M.D., to the Company’s Board of Directors. “Rich is an experienced, well-respected industry leader with an impressive medical, clinical development and regulatory background from his tenure at PhRMA, the U.S. FDA and Genzyme,” said Paula Soteropoulos, chief executive officer, Akcea.

  • Q&A: Akcea CEO Paula Soteropoulos on STEM and working with Henri Termeer
    American City Business Journalslast month

    Q&A: Akcea CEO Paula Soteropoulos on STEM and working with Henri Termeer

    The former Genzyme executive is one of relatively few female CEOs in the Massachusetts biotech industry, which is hosting the annual BIO Convention this week.

  • GlobeNewswire2 months ago

    Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of TEGSEDI(TM) (inotersen) for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). Click here to read the EMA`s press release. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union, as well as to European Economic Area members Iceland, Liechtenstein and Norway. "Today`s positive CHMP opinion is an important step toward making TEGSEDI available to people with this systemic, progressive and fatal hereditary disease that relentlessly deprives them of their independence and dignity," said Paula Soteropoulos, chief executive officer at Akcea Therapeutics.

  • GlobeNewswire2 months ago

    Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of TEGSEDI™ (inotersen) for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). Click here to read the EMA’s press release. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union, as well as to European Economic Area members Iceland, Liechtenstein and Norway. “Today’s positive CHMP opinion is an important step toward making TEGSEDI available to people with this systemic, progressive and fatal hereditary disease that relentlessly deprives them of their independence and dignity,” said Paula Soteropoulos, chief executive officer at Akcea Therapeutics.

  • MarketWatch2 months ago

    Harry Boxer’s five momentum stocks to watch, including Canopy Growth and Impinj

    A range of momentum stocks in biotech, technology and the cannabis industry have charts that are showing strength. Akcea Therapeutics Inc.(AKCA) rose $1.56, or 6.7%, to $24.85 Tuesday on volume of 336,400 shares, slightly below normal but the best in six sessions. The biopharmaceutical company announced it will present at the Jefferies Global Healthcare Conference on June 5.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Cision Ltd., FCB Financial, Akcea Therapeutics, RE/MAX, Pain Therapeutics, and Regal Beloit — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cision ...

  • GlobeNewswire2 months ago

    Akcea Therapeutics to Present at the Jefferies Global Healthcare Conference

    Akcea Therapeutics, Inc.(AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company overview at the Jefferies Global Healthcare Conference at 9:30 a.m. ET on Tuesday, June 5, 2018 in New York. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.

  • ACCESSWIRE2 months ago

    Wired News – FDA’s Advisory Committee Supports Approval of Akcea’s WAYLIVRA(TM) for Treatment of Familial Chylomicronemia Syndrome

    LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Akcea Therapeutics, Inc. (AKCA) ("Akcea"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AKCA as the Company's latest news hit the wire. On May 11, 2018, the Company, which is an affiliate of Ionis Pharmaceuticals, Inc. ("Ionis"), announced that the US Food and Drug Administration (FDA)'s Division of Metabolism and Endocrinology Products Advisory Committee voted 12-8 in favor of approving WAYLIVRATM (volanesorsen) for the treatment of people with familial chylomicronemia syndrome (FCS). Active-Investors.com is currently working on the research report for Biofrontera AG (BFRA), which also belongs to the Healthcare sector as the Company Akcea Therapeutics.

  • Why Akcea Therapeutics Rocketed Higher Today
    Motley Fool2 months ago

    Why Akcea Therapeutics Rocketed Higher Today

    An FDA advisory committee endorsed the biotech's lead drug, but an approval is far from a slam dunk.

  • GlobeNewswire2 months ago

    FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced that the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products Advisory Committee voted 12-8 to support approval of WAYLIVRATM (volanesorsen) for the treatment of people with familial chylomicronemia syndrome (FCS). The committee’s non-binding recommendation will be considered by the FDA in its review of Akcea’s New Drug Application for WAYLIVRA.  The PDUFA date for completion of the review of WAYLIVRA is August 30, 2018. “We look forward to working with the FDA to complete the final stages of regulatory review for WAYLIVRA.

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akcea Therapeutics, Inc. - AKCA

    NEW YORK , May 10, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Akcea Therapeutics, Inc. ("Akcea" or the "Company") (NASDAQ: AKCA).  Such investors ...

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akcea Therapeutics, Inc. (AKCA)

    NEW YORK , May 10, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akcea Therapeutics, Inc. ("Akcea" ...

  • Ionis Pharmaceuticals Prepares for Launch
    Motley Fool2 months ago

    Ionis Pharmaceuticals Prepares for Launch

    The biotech has the potential for two FDA approvals this year.

  • Are Options Traders Betting on a Big Move in Akcea Therapeutics (AKCA) Stock?
    Zacks2 months ago

    Are Options Traders Betting on a Big Move in Akcea Therapeutics (AKCA) Stock?

    Investors in Akcea Therapeutics (AKCA) need to pay close attention to the stock based on moves in the options market lately.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...